RARA CRAFT DATABASE for FDA Medical Devices
510(k)K190452

FDA DEVICE FACTS

Aptima BV Assay

Hologic, Inc.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEMay 23, 2019PRODUCT CODEPQA

Indications for use

The Aptima BV assay is an in vitro nucleic acid amplification test that utilizes real time transcription mediated amplification (TMA) for detection and quantitation of ribosomal RNA from bacteria associated with bacterial vaginosis (BV), including Lactobacillus (L. gasseri, L. crispatus, and L. jensenii), Gardnerella vaginalis, and Atopobium vaginae. The assay reports a qualitative result for BV and does not report results for individual organisms. The assay is intended to aid in the diagnosis of BV on the automated Panther system using clinician-collected and patient-collected vaginal swab specimens from females with a clinical presentation consistent with vaginitis and/or vaginosis. The BD MAX Vaginal Panel performed on the BD MAX System is an automated qualitative in vitro diagnostic test for the direct detection of DNA targets from bacteria associated with bacterial vaginosis (qualitative results reported based on detection and quantitation of targeted organism markers), Candida species associated with vulvovaginal candidiasis, and Trichomonas vaginalis from vaginal swabs in patients who are symptomatic for vaginitis/vaginosis. The test utilizes real-time polymerase chain reaction (PCR) for the amplification of specific DNA targets and utilizes fluorogenic target-specific hybridization probes to detect and differentiate DNA from: Bacterial vaginosis markers (Individual markers not reported) Lactobacillus spp. (L. crispatus and L. jensenii) Gardnerella Vaginalis, Atopobium vaginae, Bacterial Vaginosis Associated Bacteria-2 (BVAB- 2), Megasphaera-1, Candida spp. (C. albicans, C. dubliniensis), Candida glabrata, Candida krusei, Trichomonas vaginalis

The BD MAX Vaginal Panel is intended to aid in the diagnosis of vaginal infections in women with a clinical presentation consistent with bacterial vaginosis, vulvovaginal candidiasis and trichomoniasis. Patient Population Women with a clinical presentation of vaginitis/vaginosis Same Specimen Types Vaginal swabs in patients who are symptomatic for vaginitis/vaginosis Same Assay Controls Incorporates an Internal Control in every test. Uses external positive and negative controls. Same Test Interpretation Automated test interpretation and report generation. Same Similarities Item New Device: Aptima BV Assay (K190452) Predicate: BD MAX Vaginal Panel (DEN160001) Result Type Qualitative Same User Complexity Moderate Same

Differences Item New Device: Aptima BV Assay (K190452) Predicate: BD MAX Vaginal Panel (DEN160001) Organisms Detected Lactobacillus (L. gasseri, L. crispatus, and L. jensenii), Gardnerella vaginalis, and Atopobium vaginae Lactobacillus (L. crispatus, and L. jensenii), Lactobacillus (L. gasseri, L. crispatus, and L. jensenii), Atopobium vaginae, Bacterial Vaginosis Associated Bacteria-2 (BVAB- 2), Megasphaera-1, Candida (C. albicans,

C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata, Candida krusei, Trichomonas vaginalis Technological Principles Real-time Transcription Mediated Amplification (TMA) Real-time polymerase chain reaction (PCR) Instrumentation Panther System BD Max System Analyte Ribosomal RNA DNA

K. Standard/Guidance Document Referenced:

• CLSI EP6-A - Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Guideline

• Approach; Approved

• Guidance for Industry and FDA Staff -Nucleic Acid Based In Vitro Diagnostic Devices for Detection of Microbial Pathogens (2005)

• Guidance for Industry and FDA Staff -Design Considerations for Pivotal Clinical Investigations for Medical Devices (2013)

• Guidance for Industry and FDA Staff -Collection of Race and Ethnicity Data in Clinical Trials (2016)

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 25, 2026